You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Secondary AML and VYXEOS downloads and resources

VYXEOS dosing and administration brochure download

Preparation, dosing, and administration resources

VYXEOS dosing and administration brochure

Learn more about induction, consolidation, and outpatient administration with VYXEOS

VYXEOS nurse and pharmacist guide

A guide to dosing and administering VYXEOS, including ordering and reimbursement information

VYXEOS preparation instructions

A quick reference of VYXEOS preparation instructions

JazzCares enrollment form download

Access, reimbursement, and coverage resources

JazzCares enrollment form

The JazzCares program at Jazz Pharmaceuticals provides reimbursement and coverage information for your patients receiving VYXEOS

VYXEOS access and reimbursement information

Learn how JazzCares can help appropriate patients access VYXEOS and how our Access and Reimbursement Managers can provide expertise and support

Information about acute myeloid leukemia (AML)

The Leukemia & Lymphoma Society

www.lls.org

1-800-955-4572

INDICATION

VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.